Medidata Solutions, Inc. (NASDAQ:MDSO) – Stock analysts at SunTrust Banks dropped their Q3 2017 earnings estimates for Medidata Solutions in a research note issued on Wednesday. SunTrust Banks analyst S. Draper now expects that the company will post earnings per share of $0.19 for the quarter, down from their prior forecast of $0.21. SunTrust Banks currently has a “Buy” rating and a $90.00 target price on the stock.

Medidata Solutions (NASDAQ:MDSO) last issued its quarterly earnings results on Tuesday, July 18th. The company reported $0.31 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.28 by $0.03. Medidata Solutions had a net margin of 7.07% and a return on equity of 11.14%. The firm had revenue of $137.41 million for the quarter, compared to analyst estimates of $134.28 million. During the same period in the previous year, the business earned $0.24 EPS. The company’s revenue was up 19.9% compared to the same quarter last year. COPYRIGHT VIOLATION NOTICE: “Medidata Solutions, Inc. to Post Q3 2017 Earnings of $0.19 Per Share, SunTrust Banks Forecasts (NASDAQ:MDSO)” was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this news story on another domain, it was illegally stolen and reposted in violation of international trademark and copyright legislation. The original version of this news story can be read at https://www.thecerbatgem.com/2017/07/22/medidata-solutions-inc-to-post-q3-2017-earnings-of-0-19-per-share-suntrust-banks-forecasts-nasdaqmdso.html.

MDSO has been the topic of a number of other reports. Morgan Stanley raised their price objective on shares of Medidata Solutions from $63.00 to $74.00 and gave the company an “overweight” rating in a research note on Friday, April 28th. Needham & Company LLC raised their price objective on shares of Medidata Solutions from $65.00 to $75.00 and gave the company a “buy” rating in a research note on Thursday, April 27th. Piper Jaffray Companies raised their price objective on shares of Medidata Solutions to $87.00 and gave the company an “overweight” rating in a research note on Friday, July 7th. BidaskClub raised shares of Medidata Solutions from a “hold” rating to a “buy” rating in a research note on Wednesday, June 21st. Finally, Zacks Investment Research raised shares of Medidata Solutions from a “hold” rating to a “buy” rating and set a $75.00 price objective on the stock in a research note on Wednesday, May 3rd. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and twelve have assigned a buy rating to the company. Medidata Solutions presently has an average rating of “Buy” and a consensus price target of $78.08.

Shares of Medidata Solutions (NASDAQ:MDSO) opened at 74.78 on Friday. The firm has a 50-day moving average of $77.53 and a 200 day moving average of $63.59. The firm has a market capitalization of $4.21 billion, a price-to-earnings ratio of 126.96 and a beta of 1.81. Medidata Solutions has a 52 week low of $46.10 and a 52 week high of $85.92.

In other news, COO Michael L. Capone sold 5,000 shares of the stock in a transaction dated Monday, May 15th. The shares were sold at an average price of $69.46, for a total value of $347,300.00. Following the completion of the sale, the chief operating officer now owns 171,754 shares in the company, valued at $11,930,032.84. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, EVP Michael I. Otner sold 7,500 shares of the stock in a transaction dated Monday, May 1st. The shares were sold at an average price of $66.39, for a total transaction of $497,925.00. Following the completion of the sale, the executive vice president now owns 78,419 shares of the company’s stock, valued at approximately $5,206,237.41. The disclosure for this sale can be found here. In the last quarter, insiders sold 18,139 shares of company stock valued at $1,259,466. 5.80% of the stock is currently owned by corporate insiders.

Hedge funds have recently bought and sold shares of the company. Acrospire Investment Management LLC bought a new stake in Medidata Solutions during the first quarter worth about $121,000. LS Investment Advisors LLC increased its stake in Medidata Solutions by 44.6% in the first quarter. LS Investment Advisors LLC now owns 3,310 shares of the company’s stock worth $191,000 after buying an additional 1,021 shares during the period. World Asset Management Inc bought a new stake in Medidata Solutions during the first quarter worth about $201,000. Miles Capital Inc. bought a new stake in Medidata Solutions during the first quarter worth about $202,000. Finally, Oppenheimer & Close LLC bought a new stake in Medidata Solutions during the first quarter worth about $210,000.

Medidata Solutions Company Profile

Medidata Solutions Inc (Medidata) is a provider of cloud-based solutions for life sciences. The Company provides cloud-based solutions for clinical research in life sciences, offering platform technology that focuses on the clinical development. The Company’s plan study addresses three areas to ensure optimal study design, grant development and negotiation, and investigator payments.

Receive News & Stock Ratings for Medidata Solutions Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medidata Solutions Inc. and related stocks with our FREE daily email newsletter.